share_log

Revance Therapeutics Analyst Ratings

Revance Therapeutics Analyst Ratings

Revance Therapeutic
Benzinga Analyst Ratings ·  2023/01/24 09:28
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/24/2023 -22.41% Morgan Stanley $25 → $26 Maintains Equal-Weight
01/10/2023 13.4% Needham $35 → $38 Maintains Buy
11/16/2022 10.41% Barclays $35 → $37 Maintains Overweight
11/09/2022 -25.4% Morgan Stanley $27 → $25 Maintains Equal-Weight
10/11/2022 -19.43% Morgan Stanley → $27 Initiates Coverage On → Equal-Weight
09/22/2022 -1.52% Goldman Sachs → $33 Initiates Coverage On → Buy
09/09/2022 -10.47% Mizuho $26 → $30 Maintains Buy
09/09/2022 4.45% Barclays $22 → $35 Maintains Overweight
09/09/2022 -13.46% HC Wainwright & Co. $25 → $29 Maintains Buy
09/09/2022 4.45% Needham $25 → $35 Maintains Buy
08/25/2022 -28.38% Wells Fargo $17 → $24 Maintains Equal-Weight
10/26/2021 -34.35% Barclays $33 → $22 Maintains Overweight
10/25/2021 -49.27% Wells Fargo → $17 Downgrades Overweight → Equal-Weight
10/18/2021 -25.4% Needham $45 → $25 Maintains Buy
10/18/2021 -46.28% HC Wainwright & Co. $26 → $18 Maintains Buy
10/13/2021 -22.41% HC Wainwright & Co. $35 → $26 Maintains Buy
08/06/2021 -1.52% Barclays $32 → $33 Maintains Overweight
02/23/2021 4.45% HC Wainwright & Co. $33 → $35 Maintains Buy
01/08/2021 34.29% Needham $42 → $45 Maintains Buy
10/15/2020 25.34% Needham $36 → $42 Maintains Buy
04/16/2020 -7.49% Stifel $35 → $31 Maintains Buy
04/01/2020 4.45% Mizuho $39 → $35 Maintains Buy
03/27/2020 -28.38% HC Wainwright & Co. $28 → $24 Reiterates → Buy
03/23/2020 -55.24% Goldman Sachs $32 → $15 Downgrades Buy → Neutral
02/25/2020 19.37% Piper Sandler $37 → $40 Reiterates → Overweight
02/25/2020 7.43% Needham $32 → $36 Maintains Buy
02/18/2020 10.41% Piper Sandler $38 → $37 Maintains Overweight
01/23/2020 16.38% Mizuho $34 → $39 Maintains Buy
12/02/2019 -25.4% Goldman Sachs → $25 Initiates Coverage On → Buy
10/30/2019 -40.32% Wells Fargo $12.5 → $20 Upgrades Market Perform → Outperform
06/11/2019 -16.44% Barclays → $28 Initiates Coverage On → Overweight
02/15/2019 — Wells Fargo Initiates Coverage On → Market Perform
02/14/2019 -25.4% HC Wainwright & Co. → $25 Initiates Coverage On → Buy
01/29/2019 49.21% Stifel → $50 Initiates Coverage On → Buy
11/16/2018 22.35% Guggenheim → $41 Upgrades Neutral → Buy
09/17/2018 — JMP Securities Downgrades Market Outperform → Market Perform
03/05/2018 79.05% Goldman Sachs → $60 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
01/24/2023 -22.41% 摩根士丹利 $25 → $26 维护 等重
01/10/2023 13.4% 李约瑟 $35 → $38 维护 买
11/16/2022 10.41% 巴克莱 $35 → $37 维护 超重
11/09/2022 -25.4% 摩根士丹利 $27 → $25 维护 等重
10/11/2022 -19.43% 摩根士丹利 → $27 开始承保 →等重
09/22/2022 -1.52% 高盛 → $33 开始承保 →购买
09/09/2022 -10.47% 瑞穗 $26 → $30 维护 买
09/09/2022 4.45% 巴克莱 $22 → $35 维护 超重
09/09/2022 -13.46% HC Wainwright公司 $25 → $29 维护 买
09/09/2022 4.45% 李约瑟 $25 → $35 维护 买
08/25/2022 -28.38% 富国银行 $17 → $24 维护 等重
10/26/2021 -34.35% 巴克莱 $33 → $22 维护 超重
10/25/2021 -49.27% 富国银行 → $17 评级下调 超重→等重
10/18/2021 -25.4% 李约瑟 $45 → $25 维护 买
10/18/2021 -46.28% HC Wainwright公司 $26 → $18 维护 买
10/13/2021 -22.41% HC Wainwright公司 $35 → $26 维护 买
08/06/2021 -1.52% 巴克莱 $32 → $33 维护 超重
02/23/2021 4.45% HC Wainwright公司 $33 → $35 维护 买
01/08/2021 34.29% 李约瑟 $42 → $45 维护 买
10/15/2020 25.34% 李约瑟 $36 → $42 维护 买
04/16/2020 -7.49% Stifel $35 → $31 维护 买
04/01/2020 4.45% 瑞穗 $39 → $35 维护 买
03/27/2020 -28.38% HC Wainwright公司 $28 → $24 重申 →购买
03/23/2020 -55.24% 高盛 $32 → $15 评级下调 购买→中性
02/25/2020 19.37% 派珀·桑德勒 $37 → $40 重申 →超重
02/25/2020 7.43% 李约瑟 $32 → $36 维护 买
02/18/2020 10.41% 派珀·桑德勒 $38 → $37 维护 超重
01/23/2020 16.38% 瑞穗 $34 → $39 维护 买
12/02/2019 -25.4% 高盛 → $25 开始承保 →购买
10/30/2019 -40.32% 富国银行 $12.5 → $20 升级 市场表现优于→
06/11/2019 -16.44% 巴克莱 → $28 开始承保 →超重
02/15/2019 — 富国银行 开始承保 →市场表现
02/14/2019 -25.4% HC Wainwright公司 → $25 开始承保 →购买
01/29/2019 49.21% Stifel → $50 开始承保 →购买
11/16/2018 22.35% 古根海姆 → $41 升级 中性→购买
09/17/2018 — JMP证券 评级下调 市场表现优于→市场表现
03/05/2018 79.05% 高盛 → $60 开始承保 →购买

What is the target price for Revance Therapeutics (RVNC)?

Revance Treeutics(RVNC)的目标价格是多少？

There is no price target for Revance Therapeutics

Revance Treeutics没有价格目标

What is the most recent analyst rating for Revance Therapeutics (RVNC)?

Revance Treeutics(RVNC)的最新分析师评级是多少？

There is no analyst for Revance Therapeutics

Revance Treeutics没有分析师

When is the next analyst rating going to be posted or updated for Revance Therapeutics (RVNC)?

Revance Treeutics(RVNC)的下一次分析师评级将于何时发布或更新？

There is no next analyst rating for Revance Therapeutics

Revance Treeutics没有下一个分析师评级

Is the Analyst Rating Revance Therapeutics (RVNC) correct?

分析师对Revance Treeutics(RVNC)的评级正确吗？

There is no next analyst rating for Revance Therapeutics

Revance Treeutics没有下一个分析师评级

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发